By Hillel Aron FairWarning With the U.S. increasingly dependent on foreign manufacturers for prescription and generic drugs, the Food and Drug Administration’s problem-plagued efforts to inspect overseas plants is under growing scrutiny. A recent report by the Government Accountability Office has raised serious concerns about the FDA’s foreign inspection program and whether it’s allowing overseas drug makers […]
